Establishment Labs (NASDAQ:ESTA) Sets New 52-Week Low – Here’s What Happened

Establishment Labs Holdings Inc. (NASDAQ:ESTA)’s share price reached a new 52-week low on Monday . The stock traded as low as $29.87 and last traded at $31.03, with a volume of 104635 shares traded. The stock had previously closed at $32.05.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Stephens upgraded Establishment Labs to a “strong-buy” rating in a report on Monday, December 2nd. BTIG Research raised their price objective on Establishment Labs from $62.00 to $65.00 and gave the stock a “buy” rating in a research report on Monday, October 14th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $60.60.

Establishment Labs Stock Up 2.6 %

The stock’s 50 day simple moving average is $41.04 and its 200-day simple moving average is $42.40. The company has a debt-to-equity ratio of 5.94, a current ratio of 3.62 and a quick ratio of 2.29.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.59) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.02. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. The business had revenue of $40.23 million during the quarter, compared to analysts’ expectations of $40.60 million. During the same period in the previous year, the company earned ($1.12) earnings per share. As a group, analysts anticipate that Establishment Labs Holdings Inc. will post -2.42 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of ESTA. Assenagon Asset Management S.A. acquired a new position in shares of Establishment Labs in the 4th quarter valued at $12,898,000. Millennium Management LLC boosted its position in shares of Establishment Labs by 49.8% during the 2nd quarter. Millennium Management LLC now owns 273,605 shares of the company’s stock valued at $12,433,000 after acquiring an additional 90,943 shares in the last quarter. Rice Hall James & Associates LLC increased its stake in Establishment Labs by 10.7% in the third quarter. Rice Hall James & Associates LLC now owns 793,300 shares of the company’s stock valued at $34,326,000 after acquiring an additional 76,959 shares during the period. Stonepine Capital Management LLC acquired a new position in Establishment Labs in the third quarter worth about $3,245,000. Finally, Bamco Inc. NY lifted its stake in Establishment Labs by 13.6% during the third quarter. Bamco Inc. NY now owns 489,386 shares of the company’s stock worth $21,176,000 after purchasing an additional 58,611 shares during the period. 72.91% of the stock is owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.